Herlapsa 250mg (Lapatinib)

DESCRIPTION

Herlapsa belongs to class of antineoplastic drugs which prevents the development and spreading of cancer cells all over the body. Herlapsa is indicated for metastatic breast cancer and spreading after using of other chemotherapy drugs.

INDICATION

Herlapsa with combination of capecitabine is indicated for the treatment of advanced breast cancer after the failure of other cancer medicine.

Herlapsa is also combined with letrozole is indicated for the treatment postmenopausal women with hormone receptor positive metastatic breast cancer.

MECHANISM OF ACTION

Herlapsa is a type of classification called kinase inhibitor and act by intracellular tyrosine kinase.

Herlapsa prohibits ErbB-forced tumor cell growth in vitro and in various animal models. When combination 5-fluracil with Herlapsa created an additive effect in the 4 tumor cell lines tested. Development inhibits the Herlapsa tablet effect were examined in trastuzumab-conditioned cell lines.

Herlapsa provide selective action against breast cancer cell lines selected for long-term growth in trastuzumab-containing intracellularly. Hormone receptor-positive breast cancer cells (with ER [Estrogen Receptor] and/or PgR [Progesterone Receptor]) that co express the HER2 bear to be protection against established endocrine therapies. Synchronously hormone receptor-positive breast cancer cells that initially lack EGFR or HER2 unrecalled these receptor proteins as the tumor becomes resistant to endocrine therapy.

ADME

ABSORPTION

Poor absorbs from the GI tract. peak plasma concentration is approx. 4hrs; bioavailability is 95%. Herlapsa with food will increase the systemic exposure.

DISTRIBUTION

Plasma protein binding is 99%

METABOLISM

Herlapsa Metabolized mainly by CYP3A4 and CYP3A5.

EXCRETION

The drug eliminated dose via feces more than 14% and <2% urine.
Eliminated half-life is 24hrs.

DOSAGE MANAGEMENT

The usual dose of Herlapsa for adult suffering HER2 positive metastatic breast cancer (with Xeloda) is 1250mg once daily for 1-21days continuously repeating.
Femora Combination with Herlapsa the dose recommended is 1500mg orally once a day continuously once daily every day.
Take the drug Herlapsa tablet on an empty stomach (1hr before or 1hr after).
OVERDOSE: If overdose occurs, seek to emergency department or call poison control helpline

If you are allergic to lapatinib, then do not use the drug
If you had hepatic problem, cardio disease, an electrolytic imbalance then discusses with doctor whether it’s safe to use or not prior to Herlapsa treatment.
While patients during pregnancy, it should strictly avoid the drug because it harms the unborn baby or cause birth defects.
There is not known whether Lapatinib passes into breast milk. Hence avoid breast feeding to the infants during Herlapsa treatment

PRECAUTIONS

If you are allergic to lapatinib, then do not use the drug
If you had hepatic problem, cardio disease, an electrolytic imbalance then discusses with doctor whether it’s safe to use or not prior to Herlapsa treatment.
While patients during pregnancy, it should strictly avoid the drug because it harms the unborn baby or cause birth defects.
There is not known whether Lapatinib passes into breast milk. Hence avoid breast feeding to the infants during Herlapsa treatment.

SIDE EFFECTS

Herlapsa will cause mild to moderate side effects in patients. If symptoms cause serious the inform the doctor as soon as possible.
Common side effect of Herlapsa 250mg tablets:
Lumbar pain; diarrhae; dry skin; nail of finger toe changes; headache; in digestion problem ; decreased appetite; mild hair loss or thinning; mouth ulcers; nausea; nosebleed; redness and hands and feet will have tingling; weakness; insomnia; vomiting.
Serious side effect of Herlapsa 250mg tablets:
Severe tightness; difficulty in breathing; unusual bruising or bleeding; unusual itching; yellowing of the eyes or skin; Chest pain; urine will be dark; dizziness or light-headedness; Rapid or irregular heartbeat; pale stools; persistent loss of appetite; severe or persistent cough; severe or persistent diarrhea, nausea, vomiting and skin allergy like itching, rashes, blisters in mouth, face, lip or tongue.

DRUG INTERACTION

Interaction of Herlapsa tablet with following drugs: Artemether,

Etravirine,Pazopanib,Tracrolimus,Telithromycin,Topotecan,Tramadol,Tretinoin, Voriconazole, Ziprasidone. will increase risk of side effects and drug will not work properly and effect of Herlapsa may changes.

CONTRAINDICATIONS

Herlapsa is contraindicated to hypersensitivity condition and any products of recipients of Herlapsa

PREGNANCY & LACTATION

Herlapsa 250mg tablet has no adequate and well tolerated details about the drug Herlapsa 250mg in pregnant women. Excretion into human milk is unknown. Avoid not become pregnant while receiving Herlapsa treatment.

STORAGE 

Do not use the drug after the medication has expired.
Keep away from the children
. For Discarding the medicine, it should discuss with pharmacist. For proper dispose of chemo drugs.
Store at 20°C – 30°C.

MISSED DOSE

Take the missed dose as you remember soon before the next dose time.
If time to next dose then skip the missed dose and go for daily schedule, don’t make up with extra dose.
Please consult the doctor for further details.